MGNX - MacroGenics Janssen Biotech in licensing pact for DART molecule

MacroGenics (MGNX) has entered into a research collaboration and global license agreement with Janssen Biotech (a unit of Johnson & Johnson) for the development of a preclinical bispecific molecule with Janssen Biotech.The collaboration will incorporate MacroGenics' proprietary DART platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology.Under the terms of the agreement, Janssen will pay MacroGenics an upfront payment of $20M and will be responsible for funding all expenses. MacroGenics will also be eligible to receive up to $312M in milestone payments and tiered royalties.Further details about the transaction are not disclosed.

For further details see:

MacroGenics, Janssen Biotech in licensing pact for DART molecule